Braskem Q2 Profit Surges to R$3.3B, But Auditor Flags Going Concern Doubt
BAK is trading near its 52-week low of $2.03 (8.4% above the low).
Summary
Braskem reported a strong Q2 2026 profit of R$3.3 billion, but the auditor flagged material going concern doubt due to negative equity and a July 2026 debt default. The company is in restructuring talks and faces a new R$1.3 billion tax claim.
Key Events · Earnings and Guidance · BAK
-
Q2 Profit Reversal
Net profit of R$3,323 million in Q2 2026 versus a loss of R$390 million in Q2 2025, driven by gross profit of R$5,315 million and net exchange rate gains of R$859 million.
-
Going Concern Doubt
Auditor KPMG emphasized material uncertainty about going concern, citing negative equity of R$13,087 million consolidated and R$12,586 million parent company as of June 30, 2026.
-
July 2026 Debt Default
After the cure period expired, the Company was in default under certain financial instruments for unpaid obligations totaling R$507 million (US$98 million).
-
New Tax Assessment
In July 2026, Braskem received a R$1.3 billion tax assessment notice related to single-phase ICMS charges; loss probability assessed as possible.
Analysis · BAK · Industrial Applications And Services
A sharp recovery in gross profit and favorable exchange rate variations drove Braskem to a R$3.3 billion net profit in Q2 2026, reversing a R$390 million loss from the prior year. Yet the auditor's report emphasizes material uncertainty about the company's ability to continue as a going concern, citing negative equity of R$13.1 billion and a July 2026 default on R$507 million in financial obligations. Active debt restructuring negotiations with creditors are underway, and a new R$1.3 billion tax assessment adds further pressure. This filing is critical because it quantifies both the operational improvement and the severe liquidity crisis facing the company.
At the time of this filing, BAK was trading at $2.20 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $726M. The 52-week trading range was $2.03 to $5.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.